Floated in London last November at 290p (FTSE-250). Company website www.hikma.com

Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals
Geographic markets: USA, Europe and the Middle East & North Africa (MENA); sales in 34 countries. Headquartered in London with manufacturing facilities in the US, Jordan, Portugal, Italy and Saudi Arabia. See factsheet


Recent bullish upgrade from Merrill Lynch.

Got cash in the bank and generating more - which it intends to spend on acquisitions across North Africa and in Europe. Just announced a secondary listing on the new Dubai Index which will bring it to the attention of investors in the gulf states.

BROKER UPDATE.........

RESEARCH ALERT-Hikma: Panmure raises target price

14 Feb 2014 - 08:49
Feb 14 (Reuters) - Hikma Pharmaceuticals PLC : * Panmure raises target price to 1375p from 1350p; rating buy For a summary of rating actions and price target changes on European companies: Reuters Eikon users, click on [RCH/EUROPE] Reuters 3000Xtra users, double-click [RCH/EUROPE] Reuters Station users, click .1580 ((nyc.equities.newsroom@reuters.com); (Reuters Messaging: saqib.ahmed.thomsonreuters.com@reuters.net) ((Bangalore Newsroom +91 80 6749 1130; within U.S. +1 646 223 8780))